# Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients

> **NCT02544685** · PHASE2 · UNKNOWN · sponsor: **S&D Pharma SK s.r.o.** · enrollment: 120 (estimated)

## Conditions studied

- Febrile Neutropenia
- Neutropenia
- Infection in an Immunocompromised Host
- Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Probio-Fix Inum
- **DIETARY_SUPPLEMENT:** Beneo Synergy 1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02544685
- **Lead sponsor:** S&D Pharma SK s.r.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-07
- **Primary completion:** 2019-09
- **Final completion:** 2019-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544685, "Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02544685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*